Hartmut Grasemann

List of Publications by Year
in descending order

119	5,614	76326	85541
papers	citations	40 h-index	71 g-index

123	123	123	7132
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls. Thorax, 2023, 78, 362-367.	5.6	6
2	Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 296-305.	0.7	3
3	Nitric Oxide and Nitrogen Oxides. , 2022, , 426-442.		0
4	Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor. Journal of Cystic Fibrosis, 2022, 21, e102-e105.	0.7	2
5	Lower Airway Nitrogen Oxide Levels in Children with Primary Ciliary Dyskinesia Is Linked to Neutrophilic Inflammation. Journal of Pediatrics, 2022, 244, 230-233.	1.8	1
6	Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 623-625.	0.7	1
7	How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease be Monitored?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	2
8	Oxidative stress and obesity-related asthma. Paediatric Respiratory Reviews, 2021, 37, 18-21.	1.8	27
9	Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 977-986.	5.6	34
10	Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. International Journal of Molecular Sciences, 2021, 22, 2155.	4.1	38
11	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	7
12	Arginine Therapy for Lung Diseases. Frontiers in Pharmacology, 2021, 12, 627503.	3.5	25
13	An association of the arginase 1 gene with preschool wheezing phenotypes. Pediatric Pulmonology, 2021, 56, 1821-1822.	2.0	0
14	Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. Pediatric Pulmonology, 2021, 56, 2036-2042.	2.0	1
15	Inflammatory epithelial cytokines after in vitro respiratory syncytial viral infection are associated with reduced lung function. ERJ Open Research, 2021, 7, 00365-2021.	2.6	4
16	Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. European Respiratory Journal, 2021, 58, 2003380.	6.7	24
17	Long-term effect of CFTR modulator therapy on airway nitric oxide. European Respiratory Journal, 2020, 55, 1901113.	6.7	7
18	Potential of the Electronic Nose for the Detection of Respiratory Diseases with and without Infection. International Journal of Molecular Sciences, 2020, 21, 9416.	4.1	25

#	Article	IF	Citations
19	Neuropsychological outcomes following pediatric lung transplantation. Pediatric Pulmonology, 2020, 55, 2427-2436.	2.0	8
20	Increased Arginase Expression and Decreased Nitric Oxide in Pig Donor Lungs after Normothermic Ex Vivo Lung Perfusion. Biomolecules, 2020, 10, 300.	4.0	2
21	Lung transplantation for cystic fibrosis. Journal of Heart and Lung Transplantation, 2020, 39, 553-560.	0.6	36
22	Comparison of a handheld turbine spirometer to conventional spirometry in children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 1394-1399.	2.0	13
23	Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2000175.	6.7	2
24	Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. Genes, 2019, 10, 183.	2.4	65
25	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vasoâ€•occlusive pain. American Journal of Hematology, 2019, 94, 689-696.	4.1	17
26	L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight, 2019, 4, .	5.0	48
27	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	5.6	32
28	Transducing Airway Basal Cells with a Helper-Dependent Adenoviral Vector for Lung Gene Therapy. Human Gene Therapy, 2018, 29, 643-652.	2.7	52
29	Overcoming the Undesirable CRISPR-Cas9 Expression in Gene Correction. Molecular Therapy - Nucleic Acids, 2018, 13, 699-709.	5.1	15
30	Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Scientific Reports, 2018, 8, 14728.	3.3	42
31	A randomized clinical trial of age and genotypeâ€guided tacrolimus dosing after pediatric solid organ transplantation. Pediatric Transplantation, 2018, 22, e13285.	1.0	31
32	Regulating NETosis: Increasing pH Promotes NADPH Oxidase-Dependent NETosis. Frontiers in Medicine, 2018, 5, 19.	2.6	48
33	Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 689-691.	5.6	21
34	JNK Activation Turns on LPS- and Gram-Negative Bacteria-Induced NADPH Oxidase-Dependent Suicidal NETosis. Scientific Reports, 2017, 7, 3409.	3.3	130
35	Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations. European Respiratory Journal, 2017, 50, 1700244.	6.7	20
36	Quality of life outcomes following pediatric lung transplantation. Pediatric Pulmonology, 2017, 52, 1495-1501.	2.0	7

#	Article	IF	Citations
37	CFTR Modulator Therapy for Cystic Fibrosis. New England Journal of Medicine, 2017, 377, 2085-2088.	27.0	37
38	Asymmetric-Dimethylarginine. , 2017, , 247-254.		1
39	Association of wheeze with lung function decline in children with sickle cell disease. European Respiratory Journal, 2017, 50, 1602433.	6.7	1
40	Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1465-1474.	5.6	20
41	Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. New England Journal of Medicine, 2016, 374, 1842-1852.	27.0	456
42	Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. European Respiratory Journal, 2016, 47, 829-836.	6.7	66
43	Pediatric Emergency Department Adherence to the 2014 National Heart, Lung and Blood Institute Guidelines Targeting Analgesic Therapy in the Management of Vaso-Occlusive Pain Episodes in Children with Sickle Cell Disease: a Multicenter Perspective. Blood, 2016, 128, 1016-1016.	1.4	0
44	Pediatric Emergency Department Use of Intranasal Fentanyl to Treat Pain in Children with Sickel Cell Disease and Its Impact on Discharge Rates: A Multicenter Perspective. Blood, 2016, 128, 1306-1306.	1.4	5
45	A Lipid Mediator Hepoxilin A3 Is a Natural Inducer of Neutrophil Extracellular Traps in Human Neutrophils. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	19
46	New Developments in Cystic Fibrosis Airway Inflammation. Mediators of Inflammation, 2015, 2015, 1-2.	3.0	6
47	Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L503-L510.	2.9	42
48	Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. European Respiratory Journal, 2015, 46, 1033-1045.	6.7	120
49	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.7	62
50	The role of the endothelin-1 pathway as a biomarker for donor lung assessment in clinical ex vivo lung perfusion. Journal of Heart and Lung Transplantation, 2015, 34, 849-857.	0.6	41
51	Metabolic origins of childhood asthma. Molecular and Cellular Pediatrics, 2015, 2, 6.	1.8	4
52	SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2817-2822.	7.1	558
53	Plasma arginine metabolites reflect airway dysfunction in a murine model of allergic airway inflammation. Journal of Applied Physiology, 2015, 118, 1229-1233.	2.5	5
54	Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 727-732.	0.7	32

#	Article	IF	Citations
55	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 262-266.	0.7	45
56	Lung arginase expression and activity is increased in cystic fibrosis mouse models. Journal of Applied Physiology, 2014, 117, 284-288.	2.5	11
57	Multitracer Stable Isotope Quantification of Arginase and Nitric Oxide Synthase Activity in a Mouse Model of Pseudomonas Lung Infection. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	5
58	Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). International Journal of Molecular Sciences, 2014, 15, 6062-6071.	4.1	34
59	Asymmetric dimethylarginine and asthma. European Respiratory Journal, 2014, 43, 647-648.	6.7	12
60	Akt is essential to induce NADPH-dependent NETosis and to switch the neutrophil death to apoptosis. Blood, 2014, 123, 597-600.	1.4	133
61	Arginine Metabolism in Asthma. Immunology and Allergy Clinics of North America, 2014, 34, 767-775.	1.9	20
62	Pulmonary Venoocclusive Disease in Childhood. Chest, 2014, 146, 167-174.	0.8	24
63	Effect of Arginase Inhibition on Pulmonary L-Arginine Metabolism in Murine Pseudomonas Pneumonia. PLoS ONE, 2014, 9, e90232.	2.5	19
64	A randomized controlled trial of inhaled l-Arginine in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 468-474.	0.7	48
65	Arginine Metabolism in Patients with Cystic Fibrosis. Journal of Pediatrics, 2013, 163, 317-319.	1.8	6
66	Energy Expenditure and Nutritional Status in Pediatric Patients before and after Lung Transplantation. Journal of Pediatrics, 2013, 163, 1500-1502.	1.8	24
67	Early lung disease in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 148-157.	10.7	80
68	Increased Ornithine-Derived Polyamines Cause Airway Hyperresponsiveness in a Mouse Model of Asthma. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 694-702.	2.9	52
69	Aquagenic Wrinkling of the Palms in a Patient with Cystic Fibrosis. New England Journal of Medicine, 2013, 369, 2362-2363.	27.0	22
70	Asymmetric Dimethylarginine. Chest, 2013, 144, 367-368.	0.8	13
71	Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 726-736.	1.9	47
72	Cystic Fibrosis: Detecting Changes in Airway Inflammation with FDG PET/CT. Radiology, 2012, 264, 868-875.	7.3	42

#	Article	IF	Citations
73	Editorial [Hot Topic: New Developments in Pharmaceutical Treatments for Cystic Fibrosis (Executive) Tj ETQq1 1 0.784314 rgBT /Over	1.9	1
74	New Therapies in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 614-627.	1.9	21
75	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. Journal of Cystic Fibrosis, 2012, 11, 63-67.	0.7	22
76	Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 433-439.	0.7	84
77	Lower Airway Nitric Oxide is Increased in Children with Sickle Cell Disease. Journal of Pediatrics, 2012, 160, 93-97.	1.8	22
78	L-Ornithine Derived Polyamines in Cystic Fibrosis Airways. PLoS ONE, 2012, 7, e46618.	2.5	43
79	Nasal nitric oxide is reduced in children after solid-organ transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 108-109.	0.6	4
80	Diagnostic Value of Nasal Nitric Oxide Measured with Non-Velum Closure Techniques for Children with Primary Ciliary Dyskinesia. Journal of Pediatrics, 2011, 159, 420-424.	1.8	60
81	Augmentation of arginase 1 expression by exposure to air pollution exacerbates the airways hyperresponsiveness in murine models of asthma. Respiratory Research, 2011, 12, 19.	3.6	36
82	Asymmetric Dimethylarginine Contributes to Airway Nitric Oxide Deficiency in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1363-1368.	5.6	51
83	Asymmetric Dimethylarginine Is Increased in Asthma. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 779-785.	5.6	93
84	Innate Immune Collectin Surfactant Protein D Simultaneously Binds Both Neutrophil Extracellular Traps and Carbohydrate Ligands and Promotes Bacterial Trapping. Journal of Immunology, 2011, 187, 1856-1865.	0.8	117
85	Sputum Induction in Routine Clinical Care of Children with Cystic Fibrosis. Journal of Pediatrics, 2010, 157, 1006-1011.e1.	1.8	43
86	Do the cysteine proteinases cathepsin B and S contribute to cystic fibrosis lung disease?. Pediatric Pulmonology, 2010, 45, 845-846.	2.0	1
87	Asymmetric Dimethylarginine (ADMA) In Cystic Fibrosis Lung Disease. , 2010, , .		1
88	Exhaled Nitric Oxide in Pulmonary Diseases. Chest, 2010, 138, 682-692.	0.8	347
89	Emerging therapies for cystic fibrosis lung disease. Expert Opinion on Emerging Drugs, 2010, 15, 653-659.	2.4	29
90	Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L911-L920.	2.9	121

#	Article	IF	Citations
91	Chronic hypercapnia downregulates arginase expression and activity and increases pulmonary arterial smooth muscle relaxation in the newborn rat. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L777-L784.	2.9	12
92	Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1224-1232.	2.0	41
93	CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening. Genetic Testing and Molecular Biomarkers, 2008, 12, 25-35.	1.7	18
94	Developmental changes in arginase expression and activity in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L498-L504.	2.9	27
95	Longitudinal Decline in Lung Volume in a Population of Children with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1055-1059.	5.6	78
96	Necrotizing Pneumonia Complicated by Early and Late Pneumatoceles. Canadian Respiratory Journal, 2008, 15, 129-132.	1.6	33
97	Exhaled Nitric Oxide in Children after Accidental Exposure to Chlorine Gas. Inhalation Toxicology, 2007, 19, 895-898.	1.6	12
98	Inhalation of Moli1901 in Patients With Cystic Fibrosis. Chest, 2007, 131, 1461-1466.	0.8	116
99	Ventilatory responses to acute hypoxia in neurokinin-1 receptor deficient mice. Respiratory Physiology and Neurobiology, 2007, 159, 227-231.	1.6	5
100	Diagnostic value of serum antibodies in earlyPseudomonas aeruginosa infection in cystic fibrosis patients. Pediatric Pulmonology, 2007, 42, 249-255.	2.0	69
101	Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respiratory Research, 2006, 7, 87.	3.6	54
102	Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 65-77.	3.0	24
103	Inhaledl-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 208-212.	5.6	76
104	The Trp64Arg polymorphism in the Î² ₃ â€adrenergic receptor gene is not associated with pulmonary function in cystic fibrosis. FASEB Journal, 2006, 20, .	0.5	0
105	Interacting genetic loci cause airway hyperresponsiveness. Physiological Genomics, 2005, 21, 105-111.	2.3	41
106	Increased Arginase Activity in Cystic Fibrosis Airways. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1523-1528.	5.6	109
107	Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology, 2004, 38, 379-385.	2.0	30
108	Effects of Sex and of Gene Variants in Constitutive Nitric Oxide Synthases on Exhaled Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1113-1116.	5.6	45

#	Article	IF	Citations
109	Association of a Missense Mutation in theNOS3Gene with Exhaled Nitric Oxide Levels. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 228-231.	5.6	61
110	Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 390-394.	5.6	59
111	The Transcription Factor Early Growth-response Factor 1 Modulates Tumor Necrosis Factor- Î± , Immunoglobulin E, and Airway Responsiveness in Mice. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 778-785.	5.6	46
112	Airway nitric oxide in infants with acute wheezy bronchitis. Pediatric Allergy and Immunology, 2000, 11, 230-235.	2.6	30
113	Airway Nitric Oxide Levels in Cystic Fibrosis Patients Are Related to a Polymorphism in the Neuronal Nitric Oxide Synthase Gene. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2172-2176.	5.6	109
114	Exhaled Nitric Oxide in Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2043-2047.	5.6	115
115	Simple Tandem Repeat Polymorphisms in the Neuronal Nitric Oxide Synthase Gene in Different Ethnic Populations. Human Heredity, 1999, 49, 139-141.	0.8	30
116	Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma. Journal of Experimental Medicine, 1999, 189, 1621-1630.	8.5	195
117	Cystic fibrosis lung disease: The role of nitric oxide. Pediatric Pulmonology, 1999, 28, 442-448.	2.0	44
118	Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. Journal of Pediatrics, 1999, 135, 770-772.	1.8	97
119	Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. Journal of Clinical Investigation, 1999, 103, 507-515.	8.2	34